Adult Pertussis

Adult pertussis may be more prevalent than you think

  • CDC estimates that as many as 600,000 cases of adult pertussis may occur in the US each year [1,2]
  • Within 2 years of the introduction of Tdap vaccine, an estimated 2% of adults aged 18–64 have been immunized with a Tdap vaccine protecting them against tetanus, diphtheria, and pertussis [3]*
~2% of adults have received a Tdap between the years of 2005 and 2007 [3]

Symptoms & Severity

*Based on the Centers for Disease Control and Prevention National Immunization Survey–Adult, 2007.

Adult pertussis may be more prevalent than you think

Information on this page is general information about pertussis.

Approval of Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) for use in preventing tetanus, diphtheria, and pertussis was based on immune response data. BOOSTRIX has not been proven to have a positive impact on the potential consequences or outcomes of tetanus, diphtheria, and pertussis. To determine whether BOOSTRIX is right for your patients, please see the complete Prescribing Information.